ARTICLE | Company News
Aslan and Academia Sinica combine ASLAN003 and varlitinib in animal models
August 18, 2017 7:50 PM UTC
Aslan Pharmaceuticals Ltd. (TPEx:6497) and Academia Sinica (Taipei, Taiwan) partnered to evaluate the the combination of varlitinib (ASLAN001) and ASLAN003 in animal models for gastric, colorectal and lung cancers. The partners said the study will help them better understand "the genetic mutations responsible for varlitinib sensitivity."
Varlitinib is an oral small molecule inhibitor of EGFR, HER2 and HER4 in Phase II/III testing to treat biliary cancer. Aslan has rights to the compound from Array BioPharma Inc. (NASDAQ:ARRY) (see BioCentury, July 18, 2011). ...